German biotech company Kupando has announced an extension of its Series A funding round, securing an additional €10 million.

Target: Clinical trial

This new capital brings the total funding to €23 million and will allow the company to initiate the first human trial of its lead drug candidate, KUP101. KUP101 is a dual TLR agonist designed to target solid tumors and drug-resistant infections.

Innate Immunity

Kupando's research focuses on innate immunity, a branch of the immune system that represents the first line of defense against infections. Most immunotherapy research in oncology has focused on the adaptive immune system, the mechanism that generates antibodies. Kupando's approach aims to directly stimulate the innate immune system to fight cancer and infections.